TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12888156

Group type: EXPERIMENTAL
Intervention: Anthracycline treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No anthracycline treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 10579147

Group type: EXPERIMENTAL
Intervention: Celgene formulations (two formulations)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tortuga formulation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All three formulations
Number of subjects: 17
Study: 8738686

Group type: EXPERIMENTAL
Intervention: suxamethonium 1 mg kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: rocuronium 0.6 mg kg‐1
Number of subjects: 50
Study: 1680649

Group type: EXPERIMENTAL
Intervention: 19.2 mg oral dose of [14C]PV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9.9 mg iv dose of [14C]PV
Number of subjects: 0

Group type: COMPARATOR
Intervention: 40 mg nonradiolabeled oral dose of PV
Number of subjects: 0
Study: 6802413

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (average weekly doses of more than 4 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients who received less or no desferrioxamine)
Number of subjects: 0
Study: 31843024

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Amiloride 20 mg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Chlorthalidone or Hydrochlorothiazide with Amiloride
Number of subjects: 84
Study: 28276079

Group type: EXPERIMENTAL
Intervention: Tackling Teenage Training (TTT) program
Number of subjects: 189

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 189
Study: 25367904

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 hours
Number of subjects: 526
Study: 23592567

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZoMaxx)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (Taxus)
Number of subjects: 199
Study: 21707862

Group type: EXPERIMENTAL
Intervention: Pet therapy intervention for 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no pet therapy)
Number of subjects: 21
Study: 19779146

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Serotonin and noradrenaline selective reuptake inhibitor (SNRI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 150
Study: 17005087

Group type: EXPERIMENTAL
Intervention: Simotang oral liquid
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Glycerin enema
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (non-treated)
Number of subjects: 90
Study: 15612839

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 367

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 367
Study: 10731485

Group type: EXPERIMENTAL
Intervention: Arbutamine infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional treadmill exercise
Number of subjects: 8
Study: 8957970

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic cholecystectomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional carbon dioxide pneumoperitoneum
Number of subjects: 26
Study: 1432468

Group type: EXPERIMENTAL
Intervention: Casein-predominant formula
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whey-hydrolysate formula
Number of subjects: 28
Study: 6241563

Group type: EXPERIMENTAL
Intervention: 3 g tiapride daily for 3 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 29
Study: 30857452

Group type: EXPERIMENTAL
Intervention: ICD therapy for fast ventricular arrhythmia (VA)
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Shocks for fast VA
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing for fast VA
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: ICD therapy for slow VA
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Shocks for slow VA
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing for slow VA
Number of subjects: 1790

Group type: COMPARATOR
Intervention: No ICD therapy
Number of subjects: 1790
Study: 29356759

Group type: EXPERIMENTAL
Intervention: Modified primary continuous prophylaxis started by 25 IU/kg once per week, increased to twice or 3 times a week according to defined bleeding events.
Number of subjects: 33
Study: 27974526

Group type: EXPERIMENTAL
Intervention: Evening perindopril
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Morning perindopril
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Evening perindopril with CPAP
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Morning perindopril with CPAP
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (evening and morning)
Number of subjects: 85
Study: 25280396

Group type: EXPERIMENTAL
Intervention: Hip resurfacing (RHA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Small diameter metal‐on‐metal total hip arthroplasty (MoM THA)
Number of subjects: 82
Study: 23848944

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Internet-based problem-solving therapy (PST)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 263
Study: 21411716

Group type: EXPERIMENTAL
Intervention: Project MYTRI tobacco prevention program
Number of subjects: 14085

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14085
Study: 18167386

Group type: EXPERIMENTAL
Intervention: TY2 (Tyrian SPE and One‐Step Plus, following the manufacturer's recommendation [two coats])
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: TY4 (Tyrian SPE and One‐Step Plus, with four coats)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: OS4 (phosphoric acid and One‐Step Plus, with four coats)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: OS2 (phosphoric acid and dental adhesive [One‐Step Plus, Bisco], following the manufacturer's recommendation [two coats])
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 29
Study: 16752268

Group type: EXPERIMENTAL
Intervention: 10 mg oral micronized 17beta‐estradiol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 14521771

Group type: EXPERIMENTAL
Intervention: Low-cholesterol and low-saturated fatty acid diet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 120
Study: 11030682

Group type: EXPERIMENTAL
Intervention: 25 gauge, 16 mm, orange hub needle
Number of subjects: 119

Group type: COMPARATOR
Intervention: 23 gauge, 25 mm, blue hub needle
Number of subjects: 119
Study: 9091013

Group type: EXPERIMENTAL
Intervention: Routine amniotomy
Number of subjects: 1540

Group type: COMPARATOR
Intervention: Selective amniotomy
Number of subjects: 1540
Study: 8406348

Group type: EXPERIMENTAL
Intervention: Two 5‐micrograms doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 month (group 1)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Three 5‐micrograms doses of hepatitis B recombinant DNA yeast vaccine at 0, 1 and 6 months (group 2)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Three 10‐micrograms doses of plasma‐derived hepatitis B vaccine (group 3)
Number of subjects: 318
Study: 2869540

Group type: EXPERIMENTAL
Intervention: Temazepam 40 mg orally followed by IV saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral placebo followed by IV diazepam 10 mg (Diazemuls)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Temazepam and IV diazepam
Number of subjects: 40
Study: 29570018

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer Liquid
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (Gluma and Placebo)
Number of subjects: 33
Study: 27645620

Group type: EXPERIMENTAL
Intervention: Standard dose of ofatumumab combined with bendamustine or fludarabine and cyclophosphamide chemotherapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Mega dose of ofatumumab combined with bendamustine or fludarabine and cyclophosphamide chemotherapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 82
Study: 24835849

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 745

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study: 22799111

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50/100mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glimepiride 1/2 mg
Number of subjects: 50
Study: 19647973

Group type: EXPERIMENTAL
Intervention: Training in the Minimal Intervention for Stress‐related mental disorders with Sick leave (MISS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care provided by GPs
Number of subjects: 46
Study: 18266669

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 5 microg/min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 10 microg/min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 15 microg/min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at 20 microg/min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isoproterenol in control subjects
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoproterenol in patients with vagotonic AF
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoproterenol in patients with adrenergic AF
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoproterenol in patients with random AF
Number of subjects: 80
Study: 15715892

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice a day for 2 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 14534335

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Interferon alfa plus cytarabine
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Complete cytogenetic remission with at least 3 log reduction
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Reduction of less than 3 log
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Not in complete cytogenetic remission
Number of subjects: 1106
Study: 11302252

Group type: EXPERIMENTAL
Intervention: BCNU 150 mg/m2/i.v. followed by temozolomide 550 mg/m2/p.o. (Arm A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BCNU 100 mg/m2/i.v. followed by temozolomide 400 mg/m2/p.o. (Arm B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Temozolomide pharmacokinetics
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Screening and periodic pulmonary function testing
Number of subjects: 45
Study: 8135447

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (100 mg of recombinant tissue plasminogen activator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative strategy of watchful waiting with appropriate backup
Number of subjects: 0
Study: 2811366

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide treatment (250 mg q.i.d. with hydrocortisone 50 mg b.i.d. for 2 weeks, then 25 mg b.i.d.)
Number of subjects: 6
Study: 946507

Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis
Number of subjects: 820

Group type: COMPARATOR
Intervention: Control group (no heparin prophylaxis)
Number of subjects: 820
Study: 30638888

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent
Number of subjects: 0
Study: 28580882

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant
Number of subjects: 669

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 669
Study: 26219732

Group type: EXPERIMENTAL
Intervention: Airtraq™
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Glidescope™
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fastrach™
Number of subjects: 120
Study: 23618477

Group type: EXPERIMENTAL
Intervention: L-carnosine (1500 mg)
Number of subjects: 25
Study: 20691839

Group type: EXPERIMENTAL
Intervention: Primary PCI with adjunctive enoxaparin and abciximab
Number of subjects: 205

Group type: COMPARATOR
Intervention: Thrombolysis with enoxaparin followed by reteplase
Number of subjects: 205
Study: 18257780

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg before each main meal)
Number of subjects: 109
Study: 16774151

Group type: EXPERIMENTAL
Intervention: Mild overnight hypoxia (SaO2 approximately 90%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 11
Study: 12638640

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study: 11004354

Group type: EXPERIMENTAL
Intervention: Home management
Number of subjects: 1670
Study: 9376455

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Drug-free (after haloperidol)
Number of subjects: 21
Study: 1587076

Group type: EXPERIMENTAL
Intervention: Stopping medication under open-label conditions (weeks 190 to 210)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Stopping anorexiants under double-blind conditions (weeks 160 to 190)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Transfer from fenfluramine plus phentermine to no medication
Number of subjects: 48

Group type: COMPARATOR
Intervention: Transfer from fenfluramine plus phentermine to placebo under double-blind conditions
Number of subjects: 48
Study: 3751746

Group type: EXPERIMENTAL
Intervention: East region
Number of subjects: 0

Group type: COMPARATOR
Intervention: South-West region
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both regions
Number of subjects: 0
Study: 31661198

Group type: EXPERIMENTAL
Intervention: M72/AS01E vaccine
Number of subjects: 3575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3575
Study: 29584832

Group type: EXPERIMENTAL
Intervention: Close contact casting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 27502791

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) and arachidonic acid (AA) supplementation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Current DHA status
Number of subjects: 129
Study: 24607029

Group type: EXPERIMENTAL
Intervention: CRT-D treatment
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: CRT-D treatment with left bundle branch block (LBBB)
Number of subjects: 1370
Study: 22577917

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 200

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Propofol
Number of subjects: 200
Study: 20122737

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pascal dynamic contour tonometer (DCT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reichert Ocular Response Analyzer (ORA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of GAT, DCT, and ORA
Number of subjects: 100
Study: 17631314

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/day
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Aripiprazole 20 mg/day
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 16135354

Group type: EXPERIMENTAL
Intervention: Single-needle technique
Number of subjects: 24
Study: 12087008

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d.
Number of subjects: 503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study: 10412699

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (33 degrees C for 48 to 72 hours)
Number of subjects: 30
Study: 7725578

Group type: EXPERIMENTAL
Intervention: YAMIK sinus catheter
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional sinus punctures
Number of subjects: 131
Study: 2072226

Group type: EXPERIMENTAL
Intervention: Modified whole milk formula (M)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Lactose-hydrolyzed milk formula (HM)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Wheat noodles and whole milk (N-M)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Wheat noodles and lactose-hydrolyzed whole milk (N-HM)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both milk groups (M and HM)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Both noodle-milk groups (N-M and N-HM)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Modified whole milk (M)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Lactose-hydrolyzed milk (HM)
Number of subjects: 116
Study: 6342332

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg X 3 daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High quality bandaging
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low quality bandaging
Number of subjects: 100
Study: 30857464

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 15108

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 15108
Study: 29853236

Group type: EXPERIMENTAL
Intervention: 3D planning technique
Number of subjects: 62

Group type: COMPARATOR
Intervention: 2D planning technique
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both 2D and 3D planning techniques
Number of subjects: 62
Study: 27121690

Group type: EXPERIMENTAL
Intervention: RAI with lithium
Number of subjects: 163

Group type: COMPARATOR
Intervention: RAI alone
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: RAI with lithium (women and patients with Graves' disease)
Number of subjects: 163
Study: 24689834

Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 0
Study: 22570948

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Diet/Exercise
Number of subjects: 42
Study: 20026779

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg daily
Number of subjects: 17802

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17802
Study: 18628266

Group type: EXPERIMENTAL
Intervention: Topical conjunctival anaesthesia with a 1:1 mixture of lidocaine 2% and levobupivacaine 0.75%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Balanced salt solution
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 22
Study: 16198882

Group type: EXPERIMENTAL
Intervention: Hypertensive diastolic heart failure
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 28
Study: 12392387

Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9918344

Group type: EXPERIMENTAL
Intervention: Pallidotomy (PVP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Posteroventral stimulation (PVS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pallidotomy (PVP) and Posteroventral stimulation (PVS)
Number of subjects: 13
Study: 7572686

Group type: EXPERIMENTAL
Intervention: Lovastatin (20-40 mg/day)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 919

Group type: COMPARATOR
Intervention: Lovastatin-placebo
Number of subjects: 919
Study: 1963015

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day (4000 anti-Factor Xa IU), administered in one or two subcutaneous injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day (one or two injections daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day, begun 12 h pre-operatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 IU tds
Number of subjects: 0
Study: 380804

Group type: EXPERIMENTAL
Intervention: Levamisole, 150 mg/day orally for 3 consecutive days every other week
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 134
Study: 30064259

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation added to pulmonary rehabilitation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (control group)
Number of subjects: 45
Study: 28570161

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily (n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Letrozole (matched pairs)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sirolimus (baseline use in both groups)
Number of subjects: 17
Study: 26443655

Group type: EXPERIMENTAL
Intervention: In situ simulation (ISS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Off-site simulation (OSS)
Number of subjects: 25
Study: 23561330

Group type: EXPERIMENTAL
Intervention: Low-dose β‐conglycinin (2.3 g/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose β‐conglycinin (4.6 g/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (four casein tablets/d)
Number of subjects: 100
Study: 22717090

Group type: EXPERIMENTAL
Intervention: Risperidone with light therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 36
Study: 20643172

Group type: EXPERIMENTAL
Intervention: Goal attainment through a modified curriculum for EFNEP, with participants receiving a goal sheet after each of 6 classes.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Goal attainment related to fiber, vegetable, and water consumption goals.
Number of subjects: 54
Study: 18235414

Group type: EXPERIMENTAL
Intervention: Anti-angiogenesis treatment (humanized monoclonal antibody targeting vascular endothelial growth factor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-angiogenesis treatment (low-molecular-weight anti tyrosine kinases)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 15204276

Group type: EXPERIMENTAL
Intervention: Adaptive Cruise Control (ACC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual Driving
Number of subjects: 0